Butacaine

DB11502

small molecule approved vet_approved

Deskripsi

Struktur Molekul 2D

Berat 306.45
Wujud -

Peta Jejaring Molekuler
Legenda: Obat • Target • Gen • Enzim • (Panah → menunjukkan arah efek / relasi) • Transporter • Carrier

Profil Farmakokinetik

Waktu Paruh (Half-Life) -
Volume Distribusi -
Klirens (Clearance) -

Absorpsi

Data absorpsi tidak tersedia.

Metabolisme

Data metabolisme tidak tersedia.

Rute Eliminasi

Data eliminasi belum tersedia.

Interaksi Obat

1042 Data
Hyaluronidase (ovine) Hyaluronidase (ovine) can cause an increase in the absorption of Butacaine resulting in an increased serum concentration and potentially a worsening of adverse effects.
Hyaluronidase (human recombinant) Hyaluronidase (human recombinant) can cause an increase in the absorption of Butacaine resulting in an increased serum concentration and potentially a worsening of adverse effects.
Hyaluronidase Hyaluronidase can cause an increase in the absorption of Butacaine resulting in an increased serum concentration and potentially a worsening of adverse effects.
Lidocaine The risk or severity of methemoglobinemia can be increased when Lidocaine is combined with Butacaine.
Ropivacaine The risk or severity of methemoglobinemia can be increased when Ropivacaine is combined with Butacaine.
Bupivacaine The risk or severity of methemoglobinemia can be increased when Bupivacaine is combined with Butacaine.
Cinchocaine The risk or severity of methemoglobinemia can be increased when Cinchocaine is combined with Butacaine.
Dyclonine The risk or severity of methemoglobinemia can be increased when Dyclonine is combined with Butacaine.
Procaine The risk or severity of methemoglobinemia can be increased when Procaine is combined with Butacaine.
Prilocaine The risk or severity of methemoglobinemia can be increased when Prilocaine is combined with Butacaine.
Proparacaine The risk or severity of methemoglobinemia can be increased when Proparacaine is combined with Butacaine.
Meloxicam The risk or severity of methemoglobinemia can be increased when Meloxicam is combined with Butacaine.
Oxybuprocaine The risk or severity of methemoglobinemia can be increased when Oxybuprocaine is combined with Butacaine.
Cocaine The risk or severity of methemoglobinemia can be increased when Cocaine is combined with Butacaine.
Mepivacaine The risk or severity of methemoglobinemia can be increased when Mepivacaine is combined with Butacaine.
Levobupivacaine The risk or severity of methemoglobinemia can be increased when Levobupivacaine is combined with Butacaine.
Diphenhydramine The risk or severity of methemoglobinemia can be increased when Diphenhydramine is combined with Butacaine.
Benzocaine The risk or severity of methemoglobinemia can be increased when Benzocaine is combined with Butacaine.
Chloroprocaine The risk or severity of methemoglobinemia can be increased when Chloroprocaine is combined with Butacaine.
Phenol The risk or severity of methemoglobinemia can be increased when Phenol is combined with Butacaine.
Tetrodotoxin The risk or severity of methemoglobinemia can be increased when Tetrodotoxin is combined with Butacaine.
Benzyl alcohol The risk or severity of methemoglobinemia can be increased when Benzyl alcohol is combined with Butacaine.
Capsaicin The risk or severity of methemoglobinemia can be increased when Capsaicin is combined with Butacaine.
Etidocaine The risk or severity of methemoglobinemia can be increased when Etidocaine is combined with Butacaine.
Articaine The risk or severity of methemoglobinemia can be increased when Articaine is combined with Butacaine.
Tetracaine The risk or severity of methemoglobinemia can be increased when Tetracaine is combined with Butacaine.
Propoxycaine The risk or severity of methemoglobinemia can be increased when Propoxycaine is combined with Butacaine.
Pramocaine The risk or severity of methemoglobinemia can be increased when Pramocaine is combined with Butacaine.
Butamben The risk or severity of methemoglobinemia can be increased when Butamben is combined with Butacaine.
Oxetacaine The risk or severity of methemoglobinemia can be increased when Butacaine is combined with Oxetacaine.
Ethyl chloride The risk or severity of methemoglobinemia can be increased when Butacaine is combined with Ethyl chloride.
Butanilicaine The risk or severity of methemoglobinemia can be increased when Butacaine is combined with Butanilicaine.
Metabutethamine The risk or severity of methemoglobinemia can be increased when Butacaine is combined with Metabutethamine.
Quinisocaine The risk or severity of methemoglobinemia can be increased when Butacaine is combined with Quinisocaine.
Cetuximab The risk or severity of methemoglobinemia can be increased when Cetuximab is combined with Butacaine.
Denileukin diftitox The risk or severity of methemoglobinemia can be increased when Denileukin diftitox is combined with Butacaine.
Leuprolide The risk or severity of methemoglobinemia can be increased when Leuprolide is combined with Butacaine.
Peginterferon alfa-2a The risk or severity of methemoglobinemia can be increased when Peginterferon alfa-2a is combined with Butacaine.
Goserelin The risk or severity of methemoglobinemia can be increased when Goserelin is combined with Butacaine.
Asparaginase Escherichia coli The risk or severity of methemoglobinemia can be increased when Asparaginase Escherichia coli is combined with Butacaine.
Interferon alfa-2a The risk or severity of methemoglobinemia can be increased when Interferon alfa-2a is combined with Butacaine.
Aldesleukin The risk or severity of methemoglobinemia can be increased when Aldesleukin is combined with Butacaine.
Gemtuzumab ozogamicin The risk or severity of methemoglobinemia can be increased when Gemtuzumab ozogamicin is combined with Butacaine.
Pegaspargase The risk or severity of methemoglobinemia can be increased when Pegaspargase is combined with Butacaine.
Trastuzumab The risk or severity of methemoglobinemia can be increased when Trastuzumab is combined with Butacaine.
Rituximab The risk or severity of methemoglobinemia can be increased when Rituximab is combined with Butacaine.
Tositumomab The risk or severity of methemoglobinemia can be increased when Tositumomab is combined with Butacaine.
Alemtuzumab The risk or severity of methemoglobinemia can be increased when Alemtuzumab is combined with Butacaine.
Octreotide The risk or severity of methemoglobinemia can be increased when Octreotide is combined with Butacaine.
Interferon alfa-2b The risk or severity of methemoglobinemia can be increased when Interferon alfa-2b is combined with Butacaine.
Bevacizumab The risk or severity of methemoglobinemia can be increased when Bevacizumab is combined with Butacaine.
Masoprocol The risk or severity of methemoglobinemia can be increased when Masoprocol is combined with Butacaine.
Bortezomib The risk or severity of methemoglobinemia can be increased when Bortezomib is combined with Butacaine.
Pipobroman The risk or severity of methemoglobinemia can be increased when Pipobroman is combined with Butacaine.
Cladribine The risk or severity of methemoglobinemia can be increased when Cladribine is combined with Butacaine.
Cabergoline The risk or severity of methemoglobinemia can be increased when Cabergoline is combined with Butacaine.
Anagrelide The risk or severity of methemoglobinemia can be increased when Anagrelide is combined with Butacaine.
Carmustine The risk or severity of methemoglobinemia can be increased when Carmustine is combined with Butacaine.
Chlorotrianisene The risk or severity of methemoglobinemia can be increased when Chlorotrianisene is combined with Butacaine.
Amsacrine The risk or severity of methemoglobinemia can be increased when Amsacrine is combined with Butacaine.
Pamidronic acid The risk or severity of methemoglobinemia can be increased when Pamidronic acid is combined with Butacaine.
Bleomycin The risk or severity of methemoglobinemia can be increased when Bleomycin is combined with Butacaine.
Chlorambucil The risk or severity of methemoglobinemia can be increased when Chlorambucil is combined with Butacaine.
Raltitrexed The risk or severity of methemoglobinemia can be increased when Raltitrexed is combined with Butacaine.
Mitomycin The risk or severity of methemoglobinemia can be increased when Mitomycin is combined with Butacaine.
Bexarotene The risk or severity of methemoglobinemia can be increased when Bexarotene is combined with Butacaine.
Vindesine The risk or severity of methemoglobinemia can be increased when Vindesine is combined with Butacaine.
Valproic acid The risk or severity of methemoglobinemia can be increased when Valproic acid is combined with Butacaine.
Gefitinib The risk or severity of methemoglobinemia can be increased when Gefitinib is combined with Butacaine.
Floxuridine The risk or severity of methemoglobinemia can be increased when Floxuridine is combined with Butacaine.
Megestrol acetate The risk or severity of methemoglobinemia can be increased when Megestrol acetate is combined with Butacaine.
Tioguanine The risk or severity of methemoglobinemia can be increased when Tioguanine is combined with Butacaine.
Aminoglutethimide The risk or severity of methemoglobinemia can be increased when Aminoglutethimide is combined with Butacaine.
Vinorelbine The risk or severity of methemoglobinemia can be increased when Vinorelbine is combined with Butacaine.
Valrubicin The risk or severity of methemoglobinemia can be increased when Valrubicin is combined with Butacaine.
Sorafenib The risk or severity of methemoglobinemia can be increased when Sorafenib is combined with Butacaine.
Streptozocin The risk or severity of methemoglobinemia can be increased when Streptozocin is combined with Butacaine.
Trifluridine The risk or severity of methemoglobinemia can be increased when Trifluridine is combined with Butacaine.
Gemcitabine The risk or severity of methemoglobinemia can be increased when Gemcitabine is combined with Butacaine.
Teniposide The risk or severity of methemoglobinemia can be increased when Teniposide is combined with Butacaine.
Epirubicin The risk or severity of methemoglobinemia can be increased when Epirubicin is combined with Butacaine.
Lenalidomide The risk or severity of methemoglobinemia can be increased when Lenalidomide is combined with Butacaine.
Altretamine The risk or severity of methemoglobinemia can be increased when Altretamine is combined with Butacaine.
Flutamide The risk or severity of methemoglobinemia can be increased when Flutamide is combined with Butacaine.
Cisplatin The risk or severity of methemoglobinemia can be increased when Cisplatin is combined with Butacaine.
Alitretinoin The risk or severity of methemoglobinemia can be increased when Alitretinoin is combined with Butacaine.
Oxaliplatin The risk or severity of methemoglobinemia can be increased when Oxaliplatin is combined with Butacaine.
Erlotinib The risk or severity of methemoglobinemia can be increased when Erlotinib is combined with Butacaine.
Cyclophosphamide The risk or severity of methemoglobinemia can be increased when Cyclophosphamide is combined with Butacaine.
Toremifene The risk or severity of methemoglobinemia can be increased when Toremifene is combined with Butacaine.
Vincristine The risk or severity of methemoglobinemia can be increased when Vincristine is combined with Butacaine.
Fluorouracil The risk or severity of methemoglobinemia can be increased when Fluorouracil is combined with Butacaine.
Pentostatin The risk or severity of methemoglobinemia can be increased when Pentostatin is combined with Butacaine.
Methotrexate The risk or severity of methemoglobinemia can be increased when Methotrexate is combined with Butacaine.
Vinblastine The risk or severity of methemoglobinemia can be increased when Vinblastine is combined with Butacaine.
Medroxyprogesterone acetate The risk or severity of methemoglobinemia can be increased when Medroxyprogesterone acetate is combined with Butacaine.
Imatinib The risk or severity of methemoglobinemia can be increased when Imatinib is combined with Butacaine.
Clofarabine The risk or severity of methemoglobinemia can be increased when Clofarabine is combined with Butacaine.
Prednisone The risk or severity of methemoglobinemia can be increased when Prednisone is combined with Butacaine.
Pemetrexed The risk or severity of methemoglobinemia can be increased when Pemetrexed is combined with Butacaine.

Referensi & Sumber

Artikel (PubMed)
  • PMID: 4281307
    Guyer P, Fritze D: Dimorphism of butacaine sulfate. Arzneimittelforschung. 1974 Dec;24(12):1978-9.
  • PMID: 36855
    Jung DW, Brierley GP: Energy-dependent contraction of swollen heart mitochondria--activation by butacaine. Arch Biochem Biophys. 1979 Mar;193(1):76-87.
  • PMID: 4273911
    Henderson EG, Volle RL: Asymmetrical blockade of potassium exchange in muscle by SKF 525-A: comparison with butacaine. J Pharmacol Exp Ther. 1974 Mar;188(3):553-63.
  • PMID: 13221499
    O'MALLEY WE, FORREST JW, KRANTZ JC Jr: A note on the detection of atropine sulfate in the presence of butacaine sulfate. J Am Pharm Assoc Am Pharm Assoc. 1954 Dec;43(12):769.
  • PMID: 128352
    Fayle DR, Barritt GJ, Bygrave FL: The effect of butacaine on adenine nucleotide binding and translocation in rat liver mitochondria. Biochem J. 1975 Jun;148(3):527-31.
  • PMID: 14908875
    LOOMIS TA, JESSEPH JE, BEYER RE: Prolongation of the anticoagulant action of heparin with procaine and butacaine conjugates. J Pharmacol Exp Ther. 1952 Jan;104(1):87-92.
  • PMID: 14955790
    LOOMIS TA, JESSEPH JE: A clinical study of prolonged anticoagulant effect with repository butacaine heparin. J Pharmacol Exp Ther. 1952 Sep;106(1):83-7.
  • PMID: 6446090
    Dorris RL, Gage TW: The effects of butacaine hemisulfate on brain and heart catecholamine concentrations of the mouse. Pharmacol Res Commun. 1980 Feb;12(2):155-61.
Menampilkan 8 dari 10 artikel.

Contoh Produk & Brand

Produk: 1 • International brands: 1
Produk
  • Welders Eye Ease
    Liquid • - • Ophthalmic • Canada • OTC • Approved
International Brands
  • Butyn

Sekuens Gen/Protein (FASTA)

Sekuens dimuat saat dibutuhkan agar halaman tetap ringan.
© 2025 Digital Pharmacy Research - Universitas Esa Unggul